T1	intervention 0 32	Elevated plasma endoglin (CD105)
T2	outcome 1088 1104	overall survival
T3	iv-cont-median 1113 1116	645
T4	cv-cont-median 1121 1129	947 days
T5	outcome 836 857	clinical benefit rate
T6	iv-bin-percent 878 880	15
T7	cv-bin-percent 885 888	42%
T9	control-participants 528 530	50
T10	intervention-participants 331 334	224
T11	eligibility 335 368	metastatic breast cancer patients
T12	control-participants 428 430	50
T13	outcome 921 924	TTP
T14	outcome 640 655	plasma endoglin
T15	outcome 706 751	Elevated plasma endoglin levels were detected
T16	iv-bin-abs 755 757	26
T17	intervention-participants 761 764	224
T18	iv-bin-percent 775 780	11.6%
T8	control 431 447	control subjects
